Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Nairavoice | 1h ago 226 0 1 min read
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

The idea behind Enveda is that powerful medicines could be harnessed from plants and microbes, rather than synthesized from scratch in a lab. Viswa Colluru, an early employee of Recursion Pharmaceuticals, founded Enveda in 2019 to speed up the process of discovering these new drugs using AI and other techniques.

While AI hasn’t yet produced any FDA-approved drugs, Enveda is among the wave of companies advancing AI-discovered candidates into human clinical trials. The startup is currently testing several drugs in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.

Show Some Love By Sharing

Discover more from NAIRAVOICE.COM.NG

Enjoying this article? Support our work with a small crypto donation.

Subscribe to get the latest posts sent to your email.

Enjoyed this? A small crypto donation helps us keep publishing.
Nairavoice
Nairavoice

Contributor at NairaVoice.com.ng

Related Posts

Leave a Reply